The University of Warwick has launched a new spin-out company, VerIQ Limited, designed to transform how medical device and health technology clinical trials are designed, initiated and delivered across the UK.
Formed in partnership with University Hospitals Coventry and Warwickshire (UHCW) NHS Trust, VerIQ will combine Warwick Medical School’s academic and clinical research expertise with a dedicated commercial delivery model, creating an integrated national clinical trial platform for Medtech developers. The aim is to enable faster, higher-quality and more cost-efficient evaluation of new technologies, supporting earlier adoption across the NHS.
Dr Tim Hart, Director of Warwick Innovations, said: “VerIQ harnesses the success and strength of our scientific leadership and showcases the impact that academic–industry collaboration can achieve. By enabling this new company to commercially leverage Warwick’s existing capabilities and expertise, we can help position the region and UK at the forefront of global Medtech innovation and evidence generation.”
The launch supports the UK Government’s ambition to make the UK the destination of choice for health technology development and evaluation, accelerating the pathway for innovation adoption within the NHS.
Warwick Medical School professor and UHCW orthopaedic surgeon Andy Metcalfe, Chief Medical Officer at VerIQ, added: “When having surgery, our patients want access to the best technology available. We need to deliver world-class studies that makes the UK the first place to come to for medical innovation. VerIQ will deliver efficient, high-quality medical research to ensure that patients get access to new technologies quickly and safely, improving their care and outcomes.”
VerIQ will support Medtech innovators, from start-ups to multinational manufacturers, to design, launch and deliver clinical studies with greater speed and scientific rigour.
Dr Joe Dupere, Chief Executive Officer of VerIQ Limited, said: “The UK has the talent, infrastructure, and regulatory framework to lead the world in Medtech innovation. VerIQ Limited will transform proven research excellence into an agile commercial platform, helping to ensure that life-changing technologies reach patients faster, without compromising scientific integrity.”
Initial work will focus on orthopaedics and wider Medtech trials, combining Warwick’s translational research expertise with VerIQ’s operational capacity to streamline trial set-up, accelerate recruitment and deliver consistent, high-quality data.
